| 查看: 482 | 回复: 1 | |||
xunmeng0011铁杆木虫 (正式写手)
|
[求助]
求助硼替佐米（179324-69-7）的默克索引
|
| 求助硼替佐米（179324-69-7）的默克索引，谢谢！ |
回复此楼» 猜你喜欢
国家基金申请书模板内插入图片不可调整大小?
已经有9人回复
-
退学或坚持读
已经有20人回复
-
免疫学博士有名额，速联系
已经有14人回复
-
面上基金申报没有其他的参与者成吗
已经有4人回复
-
多组分精馏求助
已经有6人回复
-
国家级人才课题组招收2026年入学博士
已经有6人回复
baiyuefei
版主 (文学泰斗)
风雪
- LS-EPI: 1647
- 应助: 4642 (副教授)
- 贵宾: 46.969
- 金币: 658157
- 散金: 11616
- 红花: 995
- 沙发: 81
- 帖子: 69389
- 在线: 13298.6小时
- 虫号: 676696
- 注册: 2008-12-18
- 性别: GG
- 专业: 合成药物化学
- 管辖: 有机交流
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★
xunmeng0011: 金币+10, ★★★★★最佳答案, 谢谢！ 2013-11-12 08:46:21
xunmeng0011: 金币+10, ★★★★★最佳答案, 谢谢！ 2013-11-12 08:46:21
|
Title: Bortezomib CAS Registry Number: 179324-69-7 CAS Name: [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid Additional Names: N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid Manufacturers' Codes: MG-341; PS-341 Trademarks: Velcade (Millenium) Molecular Formula: C19H25BN4O4 Molecular Weight: 384.24 Percent Composition: C 59.39%, H 6.56%, B 2.81%, N 14.58%, O 16.66% Literature References: Dipeptide boronic acid proteasome inhibitor. Prepn: J. Adams et al., WO 9613266; eidem, US 5780454 (1996, 1998 both to ProScript); idem et al., Bioorg. Med. Chem. Lett. 8, 333 (1998). Pharmacology and cytotoxic activity: idem et al., Cancer Res. 59, 2615 (1999). Crystal structure in complex with the yeast 20S proteasome: M. Groll et al., Structure 14, 451 (2006). Mechanism of action study: J. Codony-Servat et al., Mol. Cancer Ther. 5, 665 (2006). Clinical trial in refractory myeloma: P. G. Richardson et al., N. Engl. J. Med. 348, 2609 (2003). Review of clinical development: idem et al., Annu. Rev. Med. 57, 33-47 (2006). Properties: Soly in water: 3.3-3.8 mg/ml (pH 2-6.5). Therap-Cat: Antineoplastic. Keywords: Antineoplastic. |
2楼2013-11-11 19:03:54